Summary
The provided FDA label excerpts are for LIPITOR (atorvastatin) and do not include St. John’s wort interaction language. The evaluated response makes multiple mechanistic and clinical-effect claims about St. John’s wort and atorvastatin that are therefore unsupported by the supplied labeling text.
Category Scores
Accurate Statements
Unsupported Statements
St. John’s wort can reduce the amount of atorvastatin in the body.
The supplied LIPITOR label excerpts do not mention St. John’s wort or any effect on atorvastatin exposure from St. John’s wort.
St. John’s wort increases activity of drug-metabolizing enzymes and drug transporters, notably CYP3A4.
No St. John’s wort-related statements are present in the provided LIPITOR label excerpts.
St. John’s wort increases activity of drug-metabolizing enzymes and drug transporters, notably P-glycoprotein.
No St. John’s wort-related statements are present in the provided LIPITOR label excerpts.
By increasing CYP3A4 and P-glycoprotein activity, St. John’s wort can lower atorvastatin levels.
No St. John’s wort-related statements are present in the provided LIPITOR label excerpts.
Lower atorvastatin levels from St. John’s wort can weaken atorvastatin’s cholesterol-lowering effect.
The supplied excerpts discuss LIPITOR lipid-lowering response and time course, but do not connect that effect to St. John’s wort or reduced atorvastatin exposure from St. John’s wort.
The main expected effect of St. John’s wort with atorvastatin is reduced atorvastatin exposure.
No St. John’s wort interaction information is included in the provided LIPITOR label excerpts.
Reduced atorvastatin exposure can result in fewer lipid-lowering benefits.
No St. John’s wort interaction information is included in the provided LIPITOR label excerpts.
A higher risk of atorvastatin side effects is not the typical concern with the pairing of atorvastatin and St. John’s wort.
The supplied excerpts do not discuss St. John’s wort–atorvastatin safety concerns.
The more practical risk of atorvastatin plus St. John’s wort is that LDL cholesterol may not come down as expected.
The supplied excerpts do not discuss St. John’s wort–atorvastatin effect on LDL response.
If LDL cholesterol does not come down as expected with atorvastatin plus St. John’s wort, it can affect long-term cardiovascular risk.
The supplied excerpts list cardiovascular risk reduction for LIPITOR, but do not provide St. John’s wort–related clinical linkage or long-term risk statements tied to that interaction.
If a patient takes atorvastatin and wants to start or continue St. John’s wort, a clinician should review the combination.
The supplied excerpts do not mention St. John’s wort, so this is not supported by the provided label text.
A common outcome when combining atorvastatin with St. John’s wort is stopping St. John’s wort.
No St. John’s wort–atorvastatin combination outcomes are described in the supplied LIPITOR label excerpts.
A common outcome when combining atorvastatin with St. John’s wort is switching to another non–enzyme-inducing option for the condition St. John’s wort is being used for.
No St. John’s wort–atorvastatin combination management or outcomes are described in the supplied LIPITOR label excerpts.
The interaction between St. John’s wort and atorvastatin can make atorvastatin less effective.
The supplied excerpts do not discuss St. John’s wort–atorvastatin effectiveness.
The effect of starting St. John’s wort can begin soon after initiation because enzyme and transporter activity can change over days.
The supplied excerpts do not mention St. John’s wort initiation timing or enzyme/transporter changes related to it.
Clinically, the impact of St. John’s wort on atorvastatin may show up as less cholesterol response at follow-up lipid testing rather than as an immediate symptom.
The supplied excerpts discuss when LIPITOR response is typically observed (within 2 weeks/4 weeks), but do not address St. John’s wort or immediate vs follow-up detection for that interaction.
Alternatives to St. John’s wort depend on what St. John’s wort is being used for.
Not addressed in the provided LIPITOR label excerpts.
St. John’s wort is commonly used for mood.
Not addressed in the provided LIPITOR label excerpts.
Alternatives that do not induce CYP3A4/P-gp are less likely to interfere with atorvastatin.
The supplied excerpts do not discuss St. John’s wort or P-gp/CYP3A4 induction concepts for that herbal product.
Contradictions
Important Omissions
Any LIPITOR label-specific interaction guidance for St. John’s wort (e.g., whether it is contraindicated or how to adjust atorvastatin dosing/precautions).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The evaluated response asserts multiple mechanistic and clinical consequences of St. John’s wort with atorvastatin despite the supplied LIPITOR label excerpts providing no St. John’s wort information. This creates material risk of inaccurate medication-interaction counseling relative to the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
St. John’s wort–atorvastatin interaction claims are not supported by the provided LIPITOR prescribing information excerpts.
Suggested Improvement
Remove or revise all St. John’s wort–specific mechanistic, exposure, LDL response, timing, and management-outcome claims unless the supplied FDA label excerpts explicitly address St. John’s wort; limit interaction discussion to label-supported CYP3A4 inhibitors/other listed interacting agents (as present in Section 7).